欧洲药品管理局调查:患者注册数据库中药械不良事件收集现状
欧洲药品管理局于2020年5月至8月对ENCePP资源数据库中的注册库开展在线调查,共15题,85家注册库中31家(36.5%)完成。大多数注册库常规收集药物信息(29/31;93.5%),其中65.5%(19/29)也收集不良事件/药物不良反应数据;收集频率、时限及向第三方提供监管数据经验差异较大。
要点
- 仅36.5%的注册库完成调查,提示对不良事件收集关注度有限。
- 93.5%的注册库常规收集药物信息,其中65.5%同时收集不良事件/药物不良反应。
- 各注册库收集与报告不良事件/药物不良反应的频率和时限差异很大。
核心结论
- 注册库中不良事件/药物不良反应数据的收集、管理与报告方式差异大,需明确真实世界数据监管使用指南并加强协作。
研究设计与样本
- 欧洲药品管理局于2020年5月向ENCePP资源数据库所列注册库发放15题在线调查,要求2020年8月前完成,本文报告汇总结果。
主要发现
- 85家注册库中31家完成调查(36.5%)。
- 29/31(93.5%)的应答注册库常规收集药物信息。
- 29家中19家(65.5%)同时收集不良事件和药物不良反应数据。
- 各注册库收集与报告不良事件/药物不良反应的频率、时限及向第三方提供监管数据的经验水平差异较大。
临床怎么用
- 临床药师利用注册库真实世界数据时,应关注其不良事件收集频率、时限和报告流程的异质性。
局限性
- 应答率低(31/85;36.5%),可能反映对该主题兴趣有限或注册库并非为常规不良事件/药物不良反应收集而设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: As patient registries are not subject to regulatory requirements on the collection of adverse events (AEs) related to medicinal products, they may not have foreseen the collection of such information on a routine basis or as part of specific data collection schemes. OBJECTIVE: The European Medicines Agency conducted a survey among registries to better understand their approach towards the collection, management and reporting of AEs related to medicines. METHOD: An online survey composed of 15 questions was distributed in May 2020 to registries listed in the European Network of Centres in Pharmacoepidemiology and Pharmacovigilance (ENCePP) resources database for completion by August 2020. Aggregated results are presented in this paper. RESULTS: One third of the registries completed the survey (31/85; 36.5%). Most of the respondents routinely collect information on medicines (29/31; 93.5%), out of which 65.5% (19/29) also collect data on AEs and adverse drug reactions (ADRs). Frequencies and timelines for collecting and reporting AEs/ADRs vary widely across registries, as does their level of experience in providing data to third parties for regulatory purposes. CONCLUSIONS: The low response rate may indicate little interest in this topic or that registries were not originally developed for routine data collection on AEs/ADRs and, ultimately, monitoring of the safety of medicines. Results indicate that clear guidance on the collection and use of real-world data in regulatory frameworks and strengthened collaboration between registry holders, academia, regulators and medicines developers are needed to achieve comprehensive and high levels of quality of safety data captured by registries to support regulatory decision making. These will hopefully be enabled by the European Medicines Regulatory Network strategy to 2025.
引用
- Plueschke K, Jonker C, Strassmann V, et al. Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database. Drug Saf. 2022. PMID: 35729468. doi:10.1007/s40264-022-01188-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。